Treatment Satisfaction and Well-Being in Patients with Myopic Choroidal Neovascularization Treated with Ranibizumab in the REPAIR Study

The Ranibizumab for the Treatment of Choroidal Neovascularisation (CNV) Secondary to Pathological Myopia (PM): an Individualized Regimen (REPAIR) trial was a prospective study exploring the efficacy and safety of intravitreal ranibizumab 0.5 mg using an individualized treatment regimen over 12 month...

Descripción completa

Detalles Bibliográficos
Autores principales: Amoaku, Winfried M., Gale, Richard P., Lotery, Andrew J., Menon, Geeta, Sivaprasad, Sobha, Petrillo, Jennifer, Quinn, Jennifer
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4454435/
https://www.ncbi.nlm.nih.gov/pubmed/26039355
http://dx.doi.org/10.1371/journal.pone.0128403

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4454435/
https://www.ncbi.nlm.nih.gov/pubmed/26039355
http://dx.doi.org/10.1371/journal.pone.0128403

Ejemplares similares